Gallium GA-68 Gozetotide Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
This Gallium GA-68 Gozetotide Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.
Decision date: 24 July 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.
Executive recommendation: GO
Decision memo
Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.
The central underwriting question is whether Gallium GA-68 Gozetotide can convert its Peptide Conjugate Radionuclide, Diagnostic radiopharmaceuticals profile and PSMA biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.
1. Asset identity and development status
| Asset | Gallium GA-68 Gozetotide (query alias: Gallium GA-68 Gozetotide) |
|---|---|
| Modality / target | Peptide Conjugate Radionuclide, Diagnostic radiopharmaceuticals; PSMA; PSMA inhibitors |
| Highest global status | Approved |
| Originator | The University of California, San Francisco |
| Active developers | Telix Pharmaceuticals (US), Inc., Grand River Aseptic Manufacturing, Inc., Telix Pharmaceuticals Ltd. |
The MCP disease footprint includes PSMA-Positive Prostatic Cancer, PSMA-Positive Castration-Resistant Prostatic Cancer, Metastatic Prostate Carcinoma. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.
2. Clinical program: design and endpoint audit
| Registry | Phase | Status | Enrollment | Lead primary endpoint |
|---|---|---|---|---|
| JPRN-jRCT2031250473 | Phase 3 | Pending | 105 | The sensitivity of 68Ga-PSMA-11 PET/CT and conventional imaging for metastatic prostate cancer in Japanese men presenting with BCR |
| NCT07674771 | Early Phase 1 | Not yet recruiting | 30 | Reduction in PSMA-positive TTV |
| NCT07682649 | Phase 1 | Not yet recruiting | 20 | Dose limiting toxicity (DLT) |
The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.
Reproduce the asset-to-trial workflow with PatSnap MCP
3. Clinical readouts: what is known
PSMAfore: A Phase III, Open-label, Multi-Center, Randomized Study Comparing 177Lu-PSMA-617 vs. a Change of Androgen Receptor-Directed Therapy in the Treatment of Taxane Naïve Men With Progressive Metastatic Castrate Resistant Prostate Cancer
Phase 3; n=469; evaluation: not stated. Reported fields: Radiographic Progression Free Survival (rPFS)(Median): Hazard Ratio (HR) = 0.41(95% CI, 0.29 - 0.56), P-Value = 0.00000001; Radiographic Progression Free Survival (rPFS)(Median) = 9.30 months (95% Confidence Interval, 6.77 - NA); Radiographic Progression Free Survival (rPFS)(Median): Hazard Ratio (HR) = 0.41(95% CI, 0.29 - 0.56), P-Value = 0.00000001
Patient-Reported Outcomes in a Randomized Trial of 18F-Fluciclovine vs68Ga-PSMA-11 PET/CT-Guided Post-Prostatectomy Radiation with Simultaneous Integrated Boosts
Not Applicable; n=119; evaluation: Positive. Reported fields: AUA(most recent) = 1.3 point ; AUA(most recent) = 1.3 point
Pharmacokinetics and dosimetry of [177Lu]Lu-PSMA-617 and [68Ga]Ga-PSMA-11 in Japanese patients with PSMA-positive mCRPC
Phase 2; n=35; evaluation: not stated. Reported fields: Chloride = 5.52 L/hr ; Chloride = 1.71 L/hr
These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.
4. Market and competitive position
Gallium GA-68 Gozetotide addresses PSMA-Positive Prostatic Cancer, PSMA-Positive Castration-Resistant Prostatic Cancer, Metastatic Prostate Carcinoma. Commercial attractiveness rests on addressable biomarker-positive patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Peptide Conjugate Radionuclide, Diagnostic radiopharmaceuticals—must demonstrate a benefit large enough to offset class-specific safety and operational costs.
The strongest market-validation signal in this screen is partner behavior: 14 matched transaction record(s) indicate that sophisticated counterparties have assigned strategic value to the asset or its rights. That does not establish net present value; probability of success, remaining R&D spend, royalties, cost sharing and territorial scope still need modeling.
5. Transaction precedent and economics
| Date | Transaction | Phase at deal | Disclosed economics |
|---|---|---|---|
| 2025-04-08 | Telix Announces Cardinal Health for Gozellix Commercial Distribution | Approved | Financial terms not disclosed |
| 2025-03-18 | Telix Announces a Joint Venture with R2pharma to commercialize and distribute Telix's therapeutic and diagnostic radiopharmaceutical products in Brazil | Approved | Financial terms not disclosed |
| 2023-11-08 | Telix and Wiik Pharma Sign Distribution Agreement for Illuccix® in the Nordic Region | Approved | Financial terms not disclosed |
Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.
6. IP and freedom-to-operate screen
No asset-specific patent-application milestone appeared in the returned milestone slice. That absence is not a freedom-to-operate conclusion; a dedicated family, claim, ownership, expiry, and legal-status search remains mandatory before signing.
The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights. Confirm that licensed patents, data and know-how track every granted territory and field.
7. Principal risks and diligence gates
- Class crowding and differentiation versus other PD-(L)1/VEGF agents
- Immune and anti-angiogenic safety, including bleeding and cardiovascular risk
- Biomarker strategy, indication selection, and head-to-head endpoint execution
Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.
8. Final go/no-go memorandum
GO
Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.
Required pre-signing gates: reproduce key efficacy analyses; complete an indication-specific safety review; run a full patent-family and freedom-to-operate search; model risk-adjusted economics by territory; and reconcile all rights, sublicenses and encumbrances.
Build your next drug-asset diligence workflow with PatSnap Life Sciences MCP Servers
Data provenance: PatSnap Drug & Asset MCP, Clinical Trials MCP, and Company & Deal Intelligence MCP; accessed 24 July 2026. Counts and status fields may change as source records update.
